Fate Therapeutics' FT522 explores treatments for lymphoma and autoimmune disorders. Read why FATE stock remains a top pick in ...

Discover how targeting E3-X ligase could revolutionize SLE treatment by enhancing anti-inflammatory effects while reducing ...

Natural treatments for lupus are typically used as complementary therapies alongside conventional treatments. Learn more ...

DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...

which tested dapirolizumab pegol as a treatment for moderate-to-severe systemic lupus erythematosus. In August 2024, Conduit Pharmaceuticals announced they will be conducting a Phase IIa clinical ...

Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary ...

In September 2024, UCB and Biogen reported successful results from their Phase III clinical trial of the PHOENYCS GO study, which tested dapirolizumab pegol as a treatment for moderate-to-severe ...

The increased risks for arterial thrombotic events (ATE), venous thromboembolism (VTE), and all-cause mortality known to be found among patients with systemic lupus erythematosus (SLE) were validated ...